|
|
|
41
|
4181BE
|
KEYTRUDA 25MG/ML INJ (MSD) PEMBROLI (C)
|
PEMBROLIZUMAB
|
KEYTRUDA
|
4ML VIAL
|
C
|
9766.5
|
9766.5032
|
VIAL
|
0
|
VIAL
|
MSD
|
MERCK SHARP & DOHME (I.A.) CORP
|
STO
|
BRYDEN STOKES LTD
|
|
1000
|
ANTINEOPLASTICS
|
2024-04-01
|
2026-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
42
|
4181BE
|
KEYTRUDA 25MG/ML INJ (MSD) PEMBROLI
|
PEMBROLIZUMAB
|
KEYTRUDA
|
4ML VIAL
|
BQ
|
9,766.50
|
9,766.50
|
VIAL
|
0
|
VIAL
|
MSD
|
MERCK SHARP & DOHME (I.A.) CORP
|
STO
|
BRYDEN STOKES LTD
|
|
1000
|
ANTINEOPLASTICS
|
2026-04-01
|
2028-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
40
|
4181BH
|
BEMABIX 25MG/ML INJ (ABB/PHA) BEVACIZUMAB
|
BEVACIZUMAB
|
BEMABIX
|
4ML VIAL
|
C
|
856.27
|
856.27
|
INJECTION
|
0
|
VIAL
|
ABB
|
ABBOTT
|
PHA
|
PHARMACY SALES CARIBBEAN
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
40
|
4181BH
|
BEMABIX 25MG/ML INJ (ABB/PHA) BEVACIZUMAB (C)
|
BEVACIZUMAB
|
BEMABIX
|
4ML VIAL
|
C
|
856.27
|
856.27
|
INJECTION
|
|
|
ABB
|
ABBOTT
|
PHA
|
PHARMACY SALES CARIBBEAN
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2023-04-18
|
Delete from contract
|
IV
|
0
|
ANTINEOPLASTICS
|
2023-03-07
|
|
|
|
40
|
4181BJ
|
BEMABIX 25MG/ML INJ (ABB/PHA) BEVACIZUMAB
|
BEVACIZUMAB
|
BEMABIX
|
16ML VIAL
|
C
|
3,811.28
|
3,811.28
|
INJECTION
|
0
|
VIAL
|
ABB
|
ABBOTT
|
PHA
|
PHARMACY SALES CARIBBEAN
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
40
|
4181BJ
|
BEMABIX 25MG/ML INJ (ABB/PHA) BEVACIZUMAB (C)
|
BEVACIZUMAB
|
BEMABIX
|
16ML VIAL
|
C
|
3811.28
|
3811.28
|
INJECTION
|
|
|
ABB
|
ABBOTT
|
PHA
|
PHARMACY SALES CARIBBEAN
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2023-03-31
|
Delete from contract
|
IV
|
0
|
ANTINEOPLASTICS
|
2023-03-07
|
|
|
|
40
|
4181BK
|
INFLIXIRIL 100MG INJ (RLS/AHI) INFLIXIMAB
|
INFLIXIMAB
|
INFLIXIRIL
|
100ML
|
C
|
1,058.52
|
1,058.52
|
INJECTION
|
0
|
VIAL
|
RLS
|
RELIANCE LIFE SCIENCES
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
41
|
4181BL
|
PHESGO 60MG/ML|60MG/ML INJ (ROC) PERTUZUMAB|TRASTUZUMAB (C)
|
PERTUZUMAB|TRASTUZUMAB
|
PHESGO
|
10ML
|
C
|
12626.62
|
12626.62
|
VIAL
|
0
|
VIAL
|
ROC
|
ROCHE SERVICIOS S.A.
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
9244
|
IMMUNOSUPPRESSIVE AGENTS
|
2024-04-01
|
2026-03-31
|
|
SC
|
0
|
IMMUNOSUPPRESSIVE AGENTS
|
|
|
|
|
42
|
4181BL
|
PHESGO 60MG/ML|60MG/ML INJ (ROC) PERTUZUMAB|TRASTUZUMAB
|
PERTUZUMAB|TRASTUZUMAB
|
PHESGO
|
10ML
|
BQ
|
12,029.26
|
12,029.26
|
VIAL
|
0
|
VIAL
|
ROC
|
ROCHE SERVICIOS S.A.
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
9244
|
IMMUNOSUPPRESSIVE AGENTS
|
2026-04-01
|
2028-03-31
|
|
SC
|
0
|
IMMUNOSUPPRESSIVE AGENTS
|
|
|
|
|
41
|
4181BR
|
BEVACIREL 25MG/ML INJ (RLS) BEVACIZUMAB (C)
|
BEVACIZUMAB
|
BEVACIREL
|
4ML VIAL
|
C
|
430.58
|
430.5825
|
VIAL
|
0
|
VIAL
|
RLS
|
RELIANCE LIFE SCIENCES
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
1000
|
ANTINEOPLASTICS
|
2024-04-01
|
2026-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
41
|
4181BS
|
BEVIXA 25MG/ML INJ (INC) BEVACIZUMAB (C)
|
BEVACIZUMAB
|
BEVIXA
|
4ML VIAL
|
C
|
925.75
|
925.7524
|
VIAL
|
0
|
VIAL
|
INC
|
INCEPTA PHARMACEUTICALS LIMITED
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
1000
|
ANTINEOPLASTICS
|
2024-04-01
|
2026-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
41
|
4181BW
|
PHESGO 1200MG|600MG INJ (ROC) PERTUZUMAB|TRASTUZUMAB (C)
|
PERTUZUMAB|TRASTUZUMAB
|
PHESGO
|
15ML VIAL
|
C
|
21270.89
|
21270.885
|
VIAL
|
0
|
VIAL
|
ROC
|
ROCHE SERVICIOS S.A.
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
1000
|
ANTINEOPLASTICS
|
2024-04-01
|
2026-03-31
|
|
SC
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
42
|
4181BY
|
KESIMPTA 20MG INJ (NVS) OFATUMUMAB
|
OFATUMUMAB
|
KESIMPTA
|
0.4ML VIAL
|
BQ
|
3,794.29
|
3,794.29
|
VIAL
|
0
|
VIAL
|
NVS
|
NOVARTIS CARIBE SA
|
COL
|
AVENTA BARBADOS
|
|
1000
|
ANTINEOPLASTICS
|
2026-04-01
|
2028-03-31
|
|
SC
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
40
|
4181C
|
ACTEMRA 20MG/ML INJ (ROC/AHI) TOCILIZUMAB
|
TOCILIZUMAB
|
ACTEMRA
|
10ML VIAL
|
C
|
706.76
|
706.76
|
INJECTION
|
0
|
VIAL
|
ROC
|
ROCHE SERVICIOS S.A.
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
41
|
4181C
|
ACTEMRA 20MG/ML INJ (ROC) TOCILIZUMAB (C)
|
TOCILIZUMAB
|
ACTEMRA
|
10ML VIAL
|
C
|
706.76
|
706.7642
|
VIAL
|
0
|
VIAL
|
ROC
|
ROCHE SERVICIOS S.A.
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
9236
|
DISEASE MODIFYING ANTIRHEUMATIC AGENTS
|
2024-04-01
|
2026-03-31
|
|
IV
|
0
|
DISEASE MODIFYING ANTIRHEUMATIC AGENTS
|
|
|
|
|
42
|
4181C
|
ACTEMRA 20MG/ML INJ (ROC) TOCILIZUMAB
|
TOCILIZUMAB
|
ACTEMRA
|
10ML VIAL
|
C
|
706.76
|
706.76
|
VIAL
|
0
|
VIAL
|
ROC
|
ROCHE SERVICIOS S.A.
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
9236
|
DISEASE MODIFYING ANTIRHEUMATIC AGENTS
|
2026-04-01
|
2028-03-31
|
|
IV
|
0
|
DISEASE MODIFYING ANTIRHEUMATIC AGENTS
|
|
|
|
|
42
|
4181CN
|
REMSIMA 100MG INJ (CET) INFLIXIMAB
|
INFLIXIMAB
|
REMSIMA
|
100MG VIAL
|
BQ
|
842.68
|
842.68
|
VIAL
|
0
|
VIAL
|
CET
|
CELLTRION
|
SBI
|
MASSY DISTRIBUTION (BDOS) LTD
|
|
1000
|
ANTINEOPLASTICS
|
2026-04-01
|
2028-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
40
|
4181D
|
ACTEMRA 20MG/ML INJ (ROC/AHI) TOCILIZUMAB
|
TOCILIZUMAB
|
ACTEMRA
|
4ML VIAL
|
C
|
282.71
|
282.71
|
INJECTION
|
0
|
VIAL
|
ROC
|
ROCHE SERVICIOS S.A.
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|
|
|
|
41
|
4181D
|
ACTEMRA 20MG/ML INJ (ROC) TOCILIZUMAB (C)
|
TOCILIZUMAB
|
ACTEMRA
|
4ML VIAL
|
C
|
282.71
|
282.7057
|
VIAL
|
0
|
VIAL
|
ROC
|
ROCHE SERVICIOS S.A.
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
9236
|
DISEASE MODIFYING ANTIRHEUMATIC AGENTS
|
2024-04-01
|
2026-03-31
|
|
IV
|
0
|
DISEASE MODIFYING ANTIRHEUMATIC AGENTS
|
|
|
|
|
42
|
4181D
|
ACTEMRA 20MG/ML INJ (ROC) TOCILIZUMAB
|
TOCILIZUMAB
|
ACTEMRA
|
4ML VIAL
|
C
|
282.71
|
282.71
|
VIAL
|
0
|
VIAL
|
ROC
|
ROCHE SERVICIOS S.A.
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
9236
|
DISEASE MODIFYING ANTIRHEUMATIC AGENTS
|
2026-04-01
|
2028-03-31
|
|
IV
|
0
|
DISEASE MODIFYING ANTIRHEUMATIC AGENTS
|
|
